# MAPPING CHROMOSOMES AND GENES IN RELATION TO LEUKEMIA

> **NIH NIH R01** · SLOAN-KETTERING INST CAN RESEARCH · 1987 · $133,871

## Abstract

Our long-term research goal is to understand the role played by chromosome
changes in the etiology and clinical behavior of human tumors.  Recently,
there has been intense activity in the cytogenetic and molecular biological
investigations of chromosome abnormality in tumor cells, especially those
that arise in the lympho-hematopoietic system.  This was catalyzed by two
developments:  (1) the conclusion from the currently available extensive
tumor cytogenetic data that several chromosome changes in tumor cells are
specific enough to serve as independent diagnostic and prognostic factors
and (b) the availability of atleast one major model of gene activation
mediated by chromosome rearrangement, namely, the activation of c-myc in B
cell neoplasia consequent upon its translocation into the Ig gene loci.
Inspite of these exciting developments much remains unknown about the
significance of chromosome change to the initiation, evolution, and
clinical behavior of tumors that arise in the lympho-hematopoietic system
and elsewhere.  In this application, we propose to continue our ongoing
studies of chromosome changes, especially rearrangements in leukemia and
lymphoma in order to further define the specificity of these changes in
relation to histologic subtypes and defined tumor etiologies, continue to
map the chromosomal sites of genes that are relavent to tumorigenesis and
to correlate their positions and movements with break points or
rearrangement, analyze the break points at the molecular level, and
identify and clone novel gene sequences that translocate into genes such as
the Ig, T cell receptor, and cellular oncogenes.  These studies, we feel,
will permit new insights into the origin and significance of gene and
chromosome instability in the development of leukemia and lymphoma.  We
will use molecular techniques in conjunction with cytogenetic methods to
better define the relationship between gene and chromosome rearrangements
and tumor histology on the one hand and clinical features of patients such
as remission and response to treatment on the other.  The patient
population for these studies will comprise adult and childhood leukemia and
lymphoma patients entered on MSKCC treatment protocols.  Methods for these
studies (extended banding cytogenetics, recombinant DNA assays, and
biostatistical analysis) are well developed in our laboratory.

## Key facts

- **NIH application ID:** 3172571
- **Project number:** 5R01CA034775-05
- **Recipient organization:** SLOAN-KETTERING INST CAN RESEARCH
- **SAM.gov UEI:** KUKXRCZ6NZC2
- **Principal Investigator:** Raju S.K. Chaganti
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $133,871
- **Award type:** 5
- **Project period:** 1983-05-01 → 1989-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3172571

## Citation

> US National Institutes of Health, RePORTER application 3172571, MAPPING CHROMOSOMES AND GENES IN RELATION TO LEUKEMIA (5R01CA034775-05). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3172571. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*